Trends of the Primary Therapy for Patients with Prostate Cancer in Nara Uro-oncological Research Group (NUORG): A Comparison Between the CaPSURE Data and the NUORG Data-Reference-Cited by-同舟云学术

Trends of the Primary Therapy for Patients with Prostate Cancer in Nara Uro-oncological Research Group (NUORG): A Comparison Between the CaPSURE Data and the NUORG Data

Published:2010-03-18 Issue:6 Volume:40 Page:588-592
ISSN:0368-2811
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:Japanese Journal of Clinical Oncology

Author:

Tanaka N.,Fujimoto K.,Hirayama A.,Yoneda T.,Yoshida K.,Hirao Y.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/40/6/588/5116520/hyq008.pdf

Reference11 articles.

1. Time Trends in Clinical Risk Stratification for Prostate Cancer: Implications for Outcomes (Data From CaPSURE)

2. Screening Men for Prostate and Colorectal Cancer in the United States

3. Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan

4. Sociodemographic and Clinical Risk Characteristics of Patients With Prostate Cancer Within the Veterans Affairs Health Care System: Data From CaPSURE

5. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Free PSA performs better than total PSA in predicting prostate volume in Chinese men with PSA levels of 2.5–9.9 ng ml⁻¹;Asian Journal of Andrology;2023

2. Trends in primary treatment for localized prostate cancer according to the availability of treatment modalities and the impact of introducing robotic surgery;International Journal of Urology;2022-08-17

3. The curative effect of androgen deprivation therapy alone is insufficient in high-risk prostate cancer;Medicine;2021-08-06

4. Trends in risk classification at diagnosis and choice of primary therapy for prostate cancer: An analysis of 10 839 patients from the Nara Urological Research and Treatment Group registry between 2004 and 2015;International Journal of Urology;2021-08-05

5. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study;Japanese Journal of Clinical Oncology;2020-03-18